Invest now
Invest now

Blog

Spotlight on Tom McDowell: Kurve’s Chief Operating Officer

Leave a Comment / Blog / By

Tom McDowell, the Chief Operating Officer for Kurve Therapeutics, is a financial and operations expert with 40 years of experience. His finely tuned moral compass helps guide Kurve through its mission to provide advanced neurodegenerative disease treatments to millions of people. He has spent decades consulting, stabilizing, and growing over 25 startups and early-stage companies …

Spotlight on Tom McDowell: Kurve’s Chief Operating Officer Read More »

Spotlight on Glenn Cornett, M.D., Ph.D: Kurve’s Chief Science Officer

Leave a Comment / Blog / By

Glenn Cornett, M.D., Ph.D., is the perfect blend of creativity and scientific brilliance. If you aren’t acquainted with the field of science, you may believe that it lacks creativity, that it sounds rigid, or is devoid of imagination. That is far from the truth — and Kurve’s Chief Science Officer is the proof of concept. …

Spotlight on Glenn Cornett, M.D., Ph.D: Kurve’s Chief Science Officer Read More »

Spotlight on Marc Giroux: CEO and Founder of Kurve Therapeutics

Leave a Comment / Blog / By

I sat down with CEO Marc Giroux to discuss his career, his motivations, Kurve Therapeutics, and how this entrepreneur is reshaping the landscape of medicine. Kurve Therapeutics’ CEO and founder is a medtech innovator, serial entrepreneur, and musician.   Marc Giroux is not your typical medtech CEO. For starters, Marc has a unique ability to see …

Spotlight on Marc Giroux: CEO and Founder of Kurve Therapeutics Read More »

Why Bypassing the Blood-Brain Barrier Is So Difficult

Leave a Comment / Blog / By

The blood-brain barrier (BBB) poses one of the most significant obstacles to treating neurological disorders. While the BBB exists to protect the brain, it also shuts out many helpful medicines along with harmful substances.  In the last three decades, there have been significant efforts to understand this shield-like barrier on the way to treating challenging …

Why Bypassing the Blood-Brain Barrier Is So Difficult Read More »

Preparing to Care for a Loved One with Alzheimer’s: Tips and Strategies for Success

Leave a Comment / Blog / By

When someone you love is diagnosed with Alzheimer’s disease, it can feel like your world is crumbling around you. The sudden onslaught of fear, uncertainty, and stress can be overwhelming. Most families want to keep their loved one close and cared for as long as possible, and often take on the caregiving role themselves. Your …

Preparing to Care for a Loved One with Alzheimer’s: Tips and Strategies for Success Read More »

The Economic Impact of Alzheimer’s Disease

Leave a Comment / Blog, Featured Posts / By

$627 Billion. That was the estimated national cost of Alzheimer’s disease in 2021.  That’s more than 10x Warren Buffett’s net worth. That’s more than most countries’ GDP. Central nervous system (CNS) disorders like Alzheimer’s disease are a global economic crisis. Without efficient treatments or a cure, Alzheimer’s remains the only disease in the top 10 …

The Economic Impact of Alzheimer’s Disease Read More »

Sign Up Now to Invest With Kurve!

*Founders, board, and management own 51% of common shares

16825 48th West Suite 434
Lynnwood, WA 98037

info@kurvetx.com
(425) 640-9249

Facebook-f Twitter Linkedin-in Instagram Youtube

Transfer Agent: KoreConX Inc.  |  Broker-Dealer: Rialto Markets LLC  |  Escrow Agent: Wilmington Trust NA The Refund Policy: There are no refunds or cancelations of commitments once the subscription agreement is signed and submitted.  Please contact compliace@rialtomarkets.com with questions regarding a cancelation or refund.

  • Rialto Markets LLC is the Onboarding Agent for this offering and is not an affiliate of nor connected with the Issuer.
  • Rialto Markets LLC is NOT placing or selling these securities on behalf of the Issuer.
  • Rialto Markets LLC is NOT soliciting this investment nor making any recommendations by collecting, reviewing, and processing your application for investment.
  • Rialto Markets LLC conducts Anti-Money Laundering, Identity, and Bad Actor Disqualification reviews of the Issuer, and ensures they are a registered business in good standing.
  • Rialto Markets LLC is NOT validating or approving the information provided by the Issuer or the Issuer itself.
  • Contact information below is provided for applicants to make inquiries and requests of Rialto Markets LLC regarding the general application process, the status of the application, or general Reg A regulation-related information. Rialto Markets LLC may direct applicants to specific sections of the Offering Statement to locate information or answers to their inquiry but does not opine or provide guidance on Issuer-related matters.

The offering will be made only by means of an offering circular. An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement which only means that the company may make sales of the securities described by that offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. The securities offered by the company are highly speculative. Investing in shares of common stock of the company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. You may obtain a copy of the Form 1-A offering circular that is part of said offering statement here. You should read the offering circular before making any investment. The offering materials and this letter may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements, which constitute forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

This investment involves a high degree of risk. This investment is suitable only for persons who can bear the economic risk for an indefinite period of time and who can afford to lose their entire investment. Furthermore, investors must understand that such investment is illiquid and is expected to continue to be illiquid for an indefinite period of time. No public market exists for the securities.

This information is presented only for the purpose of providing a general overview of clinical trials. These uses have not been approved by the U.S. Food and Drug Administration (FDA) or other regulatory authorities.

Copyright © 2022 Kurve Therapeutics